Cather Simpson appointed to FPH Board

News Release
STOCK EXCHANGE LISTINGS: NEW ZEALAND (FPH), AUSTRALIA (FPH)

Cather Simpson appointed to Fisher & Paykel Healthcare Board

Auckland, New Zealand, 30 May 2022 – Fisher & Paykel Healthcare Corporation Limited advises
that Cather Simpson, PhD, has been appointed as a non-executive director of the company with
effect from 1 June 2022.

“We are pleased to announce Cather’s appointment to the Board,” said Scott St John, Board Chair.
“With her extensive experience commercialising scientific research and involvement in a range of
high-tech companies, Cather’s perspective will be a valuable addition.”

With expertise in lasers and photonics, Dr Simpson is a professor of physics and chemical sciences
at the University of Auckland and a partner at Pacific Channel, an early-stage investment company.
She is a director of the International Society for Optics & Photonics (SPIE) and founder/director for
Orbis Diagnostics. Dr Simpson also serves on the advisory boards of the Paihau-Robinson
Research Institute at Victoria University and the New Zealand Product Accelerator.

In 2010, Dr Simpson founded and directed The Photon Factory at the University of Auckland. She is
a founder of three high-tech start-up businesses, including Engender Technologies, where she
served as Chief Science Officer from 2011 to 2021. She is a Fellow of the Royal Society of New
Zealand Te Apārangi.

Dr Simpson was born in Germany during her father’s military tour of duty. Her family later moved
back to the United States, where she went on to study at the University of Virginia and the University
of New Mexico. She has resided in New Zealand since 2007.

“I’ve long admired Fisher & Paykel Healthcare’s focus on patient outcomes and its approach to
research and development,” said Dr Simpson. “I welcome the chance to serve on the Board and I
look forward to making a contribution during this exciting phase for the company.”

The Fisher & Paykel Healthcare Board has determined that Dr Simpson will be an independent
director of the Board. She will also serve as a member of the Quality, Safety and Regulatory
Committee, effective 1 June 2022.

A resolution to elect Dr Simpson will be put to shareholders at the company’s next annual
shareholders’ meeting in August 2022.

About Fisher & Paykel Healthcare
Fisher & Paykel Healthcare is a leading designer, manufacturer and marketer of products and
systems for use in acute and chronic respiratory care, surgery and the treatment of obstructive sleep
apnea. The company’s products are sold in over 120 countries worldwide. For more information
about the company, visit our website www.fphcare.com.

ENDS

Media & Investor Contacts:
Karen Knott
GM Corporate Communications
karen.knott@fphcare.co.nz
+64 21 713 911
Hayden Brown
Investor Relations Manager
hayden.brown@fphcare.co.nz
+64 27 807 8073


Authorised by Fisher & Paykel Healthcare Corporation Limited’s Board Chair.